CenterBook Partners LP Acquires 693,386 Shares of Xeris Biopharma Holdings, Inc. $XERS

CenterBook Partners LP lifted its holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) by 99.3% in the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 1,391,590 shares of the company’s stock after acquiring an additional 693,386 shares during the quarter. CenterBook Partners LP owned 0.84% of Xeris Biopharma worth $10,924,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. AlphaQuest LLC bought a new stake in shares of Xeris Biopharma in the 3rd quarter worth approximately $35,000. Northwestern Mutual Wealth Management Co. lifted its holdings in shares of Xeris Biopharma by 179.3% in the 3rd quarter. Northwestern Mutual Wealth Management Co. now owns 7,789 shares of the company’s stock worth $63,000 after acquiring an additional 5,000 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Xeris Biopharma by 29.2% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,063 shares of the company’s stock worth $63,000 after acquiring an additional 1,820 shares during the last quarter. Kingsview Wealth Management LLC bought a new stake in shares of Xeris Biopharma in the 4th quarter worth approximately $78,000. Finally, Mercer Global Advisors Inc. ADV bought a new stake in shares of Xeris Biopharma in the 3rd quarter worth approximately $85,000. 42.75% of the stock is currently owned by institutional investors.

Xeris Biopharma Price Performance

Shares of NASDAQ XERS opened at $6.18 on Monday. The company has a quick ratio of 1.50, a current ratio of 2.12 and a debt-to-equity ratio of 17.00. Xeris Biopharma Holdings, Inc. has a 52 week low of $4.30 and a 52 week high of $10.08. The firm’s fifty day moving average is $6.10 and its 200 day moving average is $6.59. The company has a market cap of $1.07 billion, a price-to-earnings ratio of 103.00 and a beta of 0.78.

Xeris Biopharma (NASDAQ:XERS) last issued its earnings results on Thursday, May 7th. The company reported $0.01 EPS for the quarter. Xeris Biopharma had a net margin of 3.81% and a return on equity of 735.00%. The company had revenue of $83.13 million for the quarter, compared to the consensus estimate of $79.83 million. On average, equities research analysts expect that Xeris Biopharma Holdings, Inc. will post 0.12 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on XERS shares. Wall Street Zen upgraded shares of Xeris Biopharma from a “buy” rating to a “strong-buy” rating in a report on Saturday, March 7th. HC Wainwright restated a “buy” rating and issued a $10.00 price objective on shares of Xeris Biopharma in a report on Monday, March 2nd. Finally, Weiss Ratings lowered shares of Xeris Biopharma from a “hold (c-)” rating to a “sell (d+)” rating in a report on Monday, May 11th. Four research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Xeris Biopharma has an average rating of “Hold” and a consensus price target of $10.80.

Insider Buying and Selling

In related news, insider Beth Hecht sold 16,667 shares of Xeris Biopharma stock in a transaction on Monday, June 1st. The shares were sold at an average price of $6.06, for a total value of $101,002.02. Following the transaction, the insider directly owned 1,176,506 shares of the company’s stock, valued at $7,129,626.36. The trade was a 1.40% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Marla Persky sold 15,500 shares of Xeris Biopharma stock in a transaction on Wednesday, June 3rd. The stock was sold at an average price of $5.90, for a total transaction of $91,450.00. Following the completion of the transaction, the director directly owned 126,500 shares in the company, valued at approximately $746,350. The trade was a 10.92% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 127,335 shares of company stock valued at $766,733 over the last quarter. Company insiders own 4.35% of the company’s stock.

Xeris Biopharma Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.